Fox Run Management L.L.C. Grows Position in Kiniksa Pharmaceuticals International, plc $KNSA

Fox Run Management L.L.C. raised its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 105.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 27,804 shares of the company’s stock after purchasing an additional 14,241 shares during the quarter. Fox Run Management L.L.C.’s holdings in Kiniksa Pharmaceuticals International were worth $1,147,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. EverSource Wealth Advisors LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares in the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth $41,000. Quarry LP purchased a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth $44,000. Osaic Holdings Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter worth $31,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter worth $43,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 6,625 shares of the company’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $46.69, for a total value of $309,321.25. Following the transaction, the chief accounting officer owned 27,418 shares of the company’s stock, valued at $1,280,146.42. This represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the company’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total transaction of $656,259.90. Following the completion of the transaction, the director directly owned 12,546 shares in the company, valued at $628,554.60. The trade was a 51.08% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 653,301 shares of company stock valued at $34,046,073 over the last three months. Company insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International Trading Down 0.7%

Shares of KNSA stock opened at $48.70 on Wednesday. The company’s 50-day moving average price is $50.29 and its 200-day moving average price is $45.77. The stock has a market cap of $3.75 billion, a price-to-earnings ratio of 54.11 and a beta of 0.12. Kiniksa Pharmaceuticals International, plc has a twelve month low of $26.27 and a twelve month high of $59.87.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. The firm had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The company’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 EPS. As a group, equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on KNSA shares. Jefferies Financial Group upped their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Wedbush boosted their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a research report on Wednesday, April 29th. Citigroup boosted their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Canaccord Genuity Group boosted their price target on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Finally, Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday. Eight analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $60.86.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.